BOLALARDA DORI NOJO‘YA TA’SIRLARINI ANIQLASH VA MONITORING QILISH

Pulatov Firdavs Abdunabiyevich; Ruzikulov Xumoyunbek Quyli o‘g‘li; Ne’matullayev Temurbek Baxodirovich

Vol. 4 No. 1 (2026), Articles

Vol. 4 No. 1 (2026)

BOLALARDA DORI NOJO‘YA TA’SIRLARINI ANIQLASH VA MONITORING QILISH

Articles

Published 2026-02-15

Pulatov Firdavs Abdunabiyevich⁺⁻
Ruzikulov Xumoyunbek Quyli o‘g‘li⁺⁻
Ne’matullayev Temurbek Baxodirovich⁺⁻

Pulatov Firdavs Abdunabiyevich

Samarqand davlat tibbiyot universiteti, Farmatsiya fakultetining 3-bosqich talabasi

Ruzikulov Xumoyunbek Quyli o‘g‘li

Samarqand davlat tibbiyot universiteti, Pediatriya fakultetining 3-bosqich talabasi

Ne’matullayev Temurbek Baxodirovich

Samarqand davlat tibbiyot universiteti, Pediatriya fakultetining 4-bosqich talabasi

PDF

Keywords

bolalar, pediatriya, dori nojo‘ya ta’siri, farmakovigilans, dori xavfsizligi, monitoring, klinik kuzatuv, allergik reaksiyalar, toksik ta’sir, polifarmatsiya, dori o‘zaro ta’siri, risk omillari, nojo‘ya hodisa, Naranjo shkalasi, profilaktika

Abstract

Bolalarda dori vositalarining nojo‘ya ta’sirlari (DNT) pediatriya amaliyotida eng muhim klinik va farmakovigilans muammolaridan biri hisoblanadi. Chunki bolalar organizmida farmakokinetik va farmakodinamik jarayonlarning yoshga xos xususiyatlari, metabolik tizimlarning yetilmaganligi, tana vazni va suyuqliklar nisbatining o‘zgaruvchanligi hamda ko‘p hollarda dori dozasining individual moslashtirilmasligi DNT rivojlanish xavfini oshiradi. Mazkur maqolada bolalarda dori nojo‘ya ta’sirlarini aniqlash, baholash va monitoring qilishning zamonaviy yondashuvlari, klinik kuzatuv mezonlari, laborator diagnostika imkoniyatlari hamda farmakovigilans tizimining pediatriyada tutgan o‘rni ilmiy asosda tahlil qilinadi. Shuningdek, DNTlarni erta aniqlashda shifokor va hamshira nazoratining roli, ota-onalarni xabardor qilish, shubhali holatlarni hujjatlashtirish, xavf omillarini aniqlash va takroriy asoratlarning oldini olishga qaratilgan profilaktik chora-tadbirlar yoritiladi. Tadqiqot natijalariga ko‘ra, pediatriyada DNTlarni monitoring qilish tizimini kuchaytirish, standartlashtirilgan baholash algoritmlarini joriy etish hamda klinik amaliyotda dori xavfsizligi madaniyatini shakllantirish bolalar salomatligini muhofaza qilishda muhim ahamiyat kasb etadi.

PDF

References

1. World Health Organization. The Importance of Pharmacovigilance: Safety Monitoring of Medicinal Products. – Geneva: WHO Press, 2002. – 52 p.

2. World Health Organization. WHO Pharmacovigilance Indicators: A Practical Manual for the Assessment of Pharmacovigilance Systems. – Geneva: WHO, 2015. – 86 p.

3. Uppsala Monitoring Centre. The WHO Programme for International Drug Monitoring: Pharmacovigilance Guidelines. – Uppsala: UMC, 2018. – 74 p.

4. Edwards I.R., Aronson J.K. Adverse drug reactions: definitions, diagnosis, and management. – London: BMJ Publishing Group, 2000. – P. 1255–1259.

5. Naranjo C.A., Busto U., Sellers E.M. et al. A method for estimating the probability of adverse drug reactions. – Toronto: Clinical Pharmacology Publications, 1981. – P. 239–245.

6. Kearns G.L., Abdel-Rahman S.M., Alander S.W. et al. Developmental pharmacology—drug disposition, action, and therapy in infants and children. – Philadelphia: The New England Journal of Medicine Press, 2003. – P. 1157–1167.

7. DiPiro J.T., Yee G.C., Posey L.M. et al. Pharmacotherapy: A Pathophysiologic Approach (11th ed.). – New York: McGraw-Hill Education, 2020. – 2432 p.

8. Rang H.P., Dale M.M., Ritter J.M., Flower R.J. Rang and Dale’s Pharmacology (9th ed.). – London: Elsevier, 2019. – 784 p.

9. Katzung B.G., Trevor A.J. Basic and Clinical Pharmacology (15th ed.). – New York: McGraw-Hill Education, 2021. – 1256 p.

10. Avery A.J., Anderson C., Bond C.M. et al. Evaluation of patient reporting of adverse drug reactions to the UK Yellow Card Scheme. – London: Blackwell Publishing, 2011. – P. 148–156.

11. Hartwig S.C., Siegel J., Schneider P.J. Preventability and severity assessment in reporting adverse drug reactions. – Washington: American Society of Health-System Pharmacists, 1992. – P. 2229–2232.

12. European Medicines Agency. Guideline on Good Pharmacovigilance Practices (GVP). – Amsterdam: EMA Publishing, 2017. – 98 p.

13. Nelson W.E., Kliegman R.M., St. Geme J.W. Nelson Textbook of Pediatrics (21st ed.). – Philadelphia: Elsevier, 2020. – 3520 p.

14. O‘zbekiston Respublikasi Sog‘liqni saqlash vazirligi. Dori vositalari xavfsizligi va farmakovigilans bo‘yicha uslubiy qo‘llanma. – Toshkent: “Tibbiyot nashriyoti”, 2021. – 96 b.